FOLH1 and prostate cancer: In addition, a greater number of apparent lesions was found in each patient with the 68Ga-labeled bisphosphonate than with the [18F]FDG in bronchial carcinoma, the [68Ga]Ga-PSMA-617 in prostate cancer and th [99mTc]Tc-MDP in breast cancer, respectively.